Bicara Therapeutics Inc. Cash Flow Statement
BCAX / Health Care|2 years of annual SEC 10-K data (FY2023-FY2024)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 2 fiscal years. All figures from audited SEC 10-K filings.
Bicara Therapeutics Inc. used $75M in operating cash flow and negative free cash flow of $75M in FY2024.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 11.58 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 |
|---|---|---|
| Net Income | -$68.0M | -$52.0M |
| Depreciation & Amortization | $56.0K | $19.0K |
| Operating Cash Flow | -$74.8M | -$45.6M |
| Capital Expenditures | $71.0K | $586.0K |
| Free Cash Flow | -$74.8M | -$46.2M |